Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis

Kidney International

Volumn 80, Issue 9, 2011, Pages 915-925

  Anders, Hans Joachim ^a   Ryu, Mi ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

glomerulosclerosis; ischemia; leukocytes; pathology; phagocytosis; Toll

Indexed keywords

ARGINASE 1; CD150 ANTIGEN; FIBRONECTIN; GROWTH FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL DAMAGE; CELL DEATH; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; FIBROGENESIS; HUMAN; INFLAMMATION; KIDNEY CELL; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY INFECTION; KIDNEY INTERSTITIUM; MACROPHAGE; MACROPHAGE ACTIVATION; MICROENVIRONMENT; NEPHRITIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TISSUE REPAIR; WOUND HEALING;

EID: 80054728443     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.217     Document Type: Review

References (109)

1. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int 2010; 78(Suppl 119): S22-S26
2. Vernon MA, Mylonas KJ, Hughes J. Macrophages and renal fibrosis. Semin Nephrol 2010; 30: 302-317.
3. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
4. Nichols SA, Dirks W, Pearse JS et al. Early evolution of animal cell signaling and adhesion genes. Proc Natl Acad Sci USA 2006; 103: 12451-12456.
5. Larson BJ, Longaker MT, Lorenz HP. Scarless fetal wound healing: a basic science review. Plast Reconstr Surg 2010; 126: 1172-1180.
6. Gurtner GC, Werner S, Barrandon Y et al. Wound repair and regeneration. Nature 2008; 453: 314-321.
7. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341: 738-746.
8. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005; 15: 599-607.
9. Cooper L, Johnson C, Burslem F et al. Wound healing and inflammation genes revealed by array analysis of macrophageless PU.1 null mice. Genome Biol 2005; 6: R5.
10. Martin P, DSouza D, Martin J et al. Wound healing in the PU.1 null mouse-tissue repair is not dependent on inflammatory cells. Curr Biol 2003; 13: 1122-1128.
11. Macedo L, Pinhal-Enfield G, Alshits V et al. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol 2007; 171: 1774-1788.
12. Lenda DM, Kikawada E, Stanley ER et al. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J Immunol 2003; 170: 3254-3262.
13. Sindrilaru A, Peters T, Wieschalka S et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 2011; 121: 985-997.
14. Panzer U, Kurts C. T cell cross-talk with kidney dendritic cells in glomerulonephritis. J Mol Med 2010; 88: 19-26.
15. Steinmetz OM, Turner JE, Panzer U. Staying on top of things right from the start: The obsessive-compulsive disorder of regulatory T cells. J Am Soc Nephrol 2010; 21: 6-7.
16. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
17. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
18. Rees AJ. Monocyte and macrophage biology: an overview. Semin Nephrol 2010; 30: 216-233.
19. Mantovani A, Sica A, Sozzani S et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
20. Muller WA. Mechanisms of transendothelial migration of leukocytes. Circ Res 2009; 105: 223-230.
21. Anders HJ. Toll-like receptors and danger signaling in kidney injury. J Am Soc Nephrol 2010; 21: 1270-1274.
22. McDonald B, Pittman K, Menezes GB et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330: 362-366.
23. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol 2008; 181: 3733-3739.
24. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8: 279-289.
25. Krausgruber T, Blazek K, Smallie T et al. IRF5 promotes inflammatory macrophage polarization and T(H)1-T(H)17 responses. Nat Immunol 2011; 12: 231-238.
26. Fleetwood AJ, Lawrence T, Hamilton JA et al. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol 2007; 178: 5245-5252.
27. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544.
28. Verreck FA, de Boer T, Langenberg DM et al. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol 2006; 79: 285-293.
29. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010; 10: 712-723.
30. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65.
31. Ryu M, Kulkarni OP, Radomska E et al. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-alpha-mediated podocyte loss. Kidney Int 2011; 79: 189-198.
32. Lassen S, Lech M, Rommele C et al. Ischemia reperfusion induces IFN regulatory factor 4 in renal dendritic cells, which suppresses postischemic inflammation and prevents acute renal failure. J Immunol 2010; 185: 1976-1983.
33. Duffield JS, Erwig LP, Wei X et al. Activated macrophages direct apoptosis and suppress mitosis of mesangial cells. J Immunol 2000; 164: 2110-2119.
34. Misseri R, Meldrum DR, Dinarello CA et al. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005; 288: F406-F411.
35. Ikezumi Y, Atkins RC, Nikolic-Paterson DJ. Interferon-gamma augments acute macrophage-mediated renal injury via a glucocorticoid-sensitive mechanism. J Am Soc Nephrol 2003; 14: 888-898.
36. Anders HJ, Vielhauer V, Eis V et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004; 18: 534-536.
37. Patole PS, Grone HJ, Segerer S et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005; 16: 1326-1338.
38. Patole PS, Pawar RD, Lichtnekert J et al. Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J Autoimmun 2007; 29: 52-59.
39. Pawar RD, Patole PS, Ellwart A et al. Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol 2006; 17: 3365-3373.
40. Pawar RD, Patole PS, Zecher D et al. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 2006; 17: 141-149.
41. Allam R, Pawar RD, Kulkarni OP et al. Viral 50-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. Eur J Immunol 2008; 38: 3487-3498.
42. Anders HJ, Banas B, Linde Y et al. Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. J Am Soc Nephrol 2003; 14: 317-326.
43. Jose MD, Ikezumi Y, van Rooijen N et al. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation 2003; 76: 1015-1022.
44. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66: 480-485.
45. Swaminathan S, Griffin MD. First responders: understanding monocyte-lineage traffic in the acutely injured kidney. Kidney Int 2008; 74: 1509-1511.
46. Lee S, Huen S, Nishio H et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22: 317-326.
47. Wang Y, Cao Q, Zheng G et al. By homing to the kidney, activated macrophages potently exacerbate renal injury. Am J Pathol 2008; 172: 1491-1499.
48. Duffield JS, Tipping PG, Kipari T et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005; 167: 1207-1219.
49. Kitamoto K, Machida Y, Uchida J et al. Effects of liposome clodronate on renal leukocyte populations and renal fibrosis in murine obstructive nephropathy. J Pharmacol Sci 2009; 111: 285-292.
50. Anders HJ, Frink M, Linde Y et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003; 170: 5658-5666.
51. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2 Nat Immunol 2006; 7: 311-317.
52. Kulkarni O, Pawar RD, Purschke W et al. Spiegelmer inhibition of CCL2/ MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007; 18: 2350-2358.
53. Kulkarni O, Eulberg D, Selve N et al. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J Pharmacol Exp Ther 2009; 328: 371-377.
54. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522-3530.
55. Clauss S, Gross O, Kulkarni O et al. Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy. J Pathol 2009; 218: 40-47.
56. Hotchkiss RS, Strasser A, McDunn JE et al. Cell death. N Engl J Med 2009; 361: 1570-1583.
57. Savill J, Gregory C, Haslett C. Cell biology. Eat me or die. Science 2003; 302: 1516-1517.
58. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997; 61: 375-380.
59. Lucas M, Stuart LM, Savill J et al. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol 2003; 171: 2610-2615.
60. Duffield JS. Macrophages and immunologic inflammation of the kidney. Semin Nephrol 2010; 30: 234-254.
61. Castano AP, Lin SL, Surowy T et al. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009; 1: 5ra13.
62. Liu G, Ma H, Qiu L et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol 2010; 89: 130-142.
63. Wang W, Huang XR, Li AG et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7 J Am Soc Nephrol 2005; 16: 1371-1383.
64. Negishi H, Ohba Y, Yanai H et al. Negative regulation of Toll-likereceptor signaling by IRF-4 Proc Natl Acad Sci USA 2005; 102: 15989-15994.
65. Satoh T, Takeuchi O, Vandenbon A et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010; 11: 936-944.
66. El Chartouni C, Schwarzfischer L, Rehli M. Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of alternative macrophage priming. Immunobiology 2010; 215: 821-825.
67. Ishii M, Wen H, Corsa CA et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009; 114: 3244-3254.
68. Filardy AA, Pires DR, Nunes MP et al. Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low)IL-10(high) regulatory phenotype in macrophages. J Immunol 2010; 185: 2044-2050.
69. Huang XR, Kitching AR, Tipping PG et al. Interleukin-10 inhibits macrophage-induced glomerular injury. J Am Soc Nephrol 2000; 11: 262-269.
70. Cao Q, Wang Y, Zheng D et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J Am Soc Nephrol 2010; 21: 933-942.
71. Kluth DC, Ainslie CV, Pearce WP et al. Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. J Immunol 2001; 166: 4728-4736.
72. Wang Y, Wang YP, Zheng G et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007; 72: 290-299.
73. Zheng D, Wang Y, Cao Q et al. Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus. Nephron Exp Nephrol 2011; 118: e87-e99.
74. Ikezumi Y, Suzuki T, Karasawa T et al. Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis. Am J Nephrol 2010; 31: 273-282.
75. Ghielli M, Verstrepen WA, Nouwen EJ et al. Inflammatory cells in renal regeneration. Ren Fail 1996; 18: 355-375.
76. Barczyk K, Ehrchen J, Tenbrock K et al. Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor A3 Blood 2010; 116: 446-455.
77. Bertalan R, Patocs A, Vasarhelyi B et al. Association between birth weight in preterm neonates and the BclI polymorphism of the glucocorticoid receptor gene. J Steroid Biochem Mol Biol 2008; 111: 91-94.
78. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009; 1796: 11-18.
79. Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-355.
80. Solinas G, Germano G, Mantovani A et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-1073.
81. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819-1834.
82. Yang L, Besschetnova TY, Brooks CR et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543 (1p following 143).
83. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6: 643-656.
84. Vielhauer V, Kulkarni O, Reichel CA et al. Targeting the recruitment of monocytes and macrophages in renal disease. Semin Nephrol 2010; 30: 318-333.
85. Ninichuk V, Anders HJ. Chemokine receptor CCR1: a new target for progressive kidney disease. Am J Nephrol 2005; 25: 365-372.
86. Ninichuk V, Khandoga AG, Segerer S et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007; 170: 1267-1276.
87. Vielhauer V, Berning E, Eis V et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephritic syndrome. Kidney Int 2004; 66: 2264-2278.
88. Eis V, Luckow B, Vielhauer V et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 2004; 15: 337-347.
89. Anders HJ, Vielhauer V, Frink M et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002; 109: 251-259.
90. Turner JE, Paust HJ, Steinmetz OM et al. CCR5 deficiency aggravates crescentic glomerulonephritis in mice. J Immunol 2008; 181: 6546-6556.
91. Dehmel S, Wang S, Schmidt C et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome. Eur J Immunol 2010; 40: 267-278.
92. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006; 8: 145-150.
93. Pilling D, Fan T, Huang D et al. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 2009; 4: e7475.
94. Schmidt M, Sun G, Stacey MA et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003; 171: 380-389.
95. Niedermeier M, Reich B, Rodriguez Gomez M et al. CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci USA 2009; 106: 17892-17897.
96. Sakai N, Furuichi K, Shinozaki Y et al. Fibrocytes are involved in the pathogenesis of human chronic kidney disease. Hum Pathol 2010; 41: 672-678.
97. Lin SL, Kisseleva T, Brenner DA et al. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173: 1617-1627.
98. Popov Y, Sverdlov DY, Bhaskar KR et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G323-G334.
99. Duffield JS, Forbes SJ, Constandinou CM et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
100. Fallowfield JA, Mizuno M, Kendall TJ et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007; 178: 5288-5295.
101. Ronco P, Chatziantoniou C. Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int 2008; 74: 873-878.
102. Fioretto P, Steffes MW, Sutherland DE et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75.
103. Ruggenenti P, Perna A, Benini R et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999; 10: 997-1006.
104. Remuzzi A, Gagliardini E, Sangalli F et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 2006; 69: 1124-1130.
105. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968.
106. Zeisberg M, Khurana M, Rao VH et al. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 2006; 3: e100.
107. Rao VH, Meehan DT, Delimont D et al. Role for macrophage metalloelastase in glomerular basement membrane damage associated with alport syndrome. Am J Pathol 2006; 169: 32-46.
108. Thomas JA, Pope C, Wojtacha D et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration and function. Hepatology 2011; 53: 2003-2015.
109. Ninichuk V, Gross O, Segerer S et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006; 70: 121-129.